KNIGHT, Andrea, Stephen MACKINNON and Mark W. LOWDELL. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy. United Kingdom: Oxford, England : ISIS Medical Media, vol. 14, No 9, p. 1110-8, 9 pp. ISSN 1465-3249. doi:10.3109/14653249.2012.700766. 2012.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells
Authors KNIGHT, Andrea, Stephen MACKINNON and Mark W. LOWDELL.
Edition Cytotherapy, United Kingdom, Oxford, England : ISIS Medical Media, 2012, 1465-3249.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.055
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3109/14653249.2012.700766
UT WoS 000308943200009
Keywords in English cytotoxicity; flow cytometry; gamma-delta cells; immunotherapy; multiple myeloma
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 23/4/2014 15:18.
Abstract
Human gamma-delta (gamma-delta) T cells are potent effector lymphocytes of innate immunity involved in anti-tumor immune surveillance. However, the Vdelta1 gamma-delta T-cell subset targeting multiple myeloma (MM) has not previously been investigated. We have shown for the first time that Vdelta1 T cells are highly myeloma-reactive and have therefore established Vdelta1 gamma-delta T cells as a potential candidate for a novel tumor immunotherapy.
PrintDisplayed: 29/3/2024 09:22